Last reviewed · How we verify
Jetrea (OCRIPLASMIN)
At a glance
| Generic name | OCRIPLASMIN |
|---|---|
| Sponsor | Thrombogenics, Inc |
| Drug class | Proteolytic Enzyme |
| Modality | Recombinant protein |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 2012 |
Approved indications
- Vitreomacular traction syndrome
Common side effects
Key clinical trials
- Vitreopapillary Interface and Optic Disc Morphology
- Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR (PHASE2)
- Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (PHASE4)
- Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema (PHASE1,PHASE2)
- Phase I RVC With Ocriplasmin for CRVO (PHASE1)
- Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
- Assessment of Patients Treated With JETREA® for Vitreomacular Traction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jetrea CI brief — competitive landscape report
- Jetrea updates RSS · CI watch RSS
- Thrombogenics, Inc portfolio CI